<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Biologic therapies for tendon and muscle injury</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Biologic therapies for tendon and muscle injury</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Biologic therapies for tendon and muscle injury</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Young, MBBS, FACSEP, DRCOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dijkstra, FFSEM (UK)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Fricker, MBBS, FACSP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Grayzel, MD, FAAEM</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22673008"><span class="h1">INTRODUCTION AND DEFINITIONS</span><span class="headingEndMark"> — </span>Biologic therapies, often referred to as "biologics," are a class of nonpharmacologic treatments being used for a variety of conditions in many areas of medicine. Proponents of biologic therapies in musculoskeletal medicine claim that they improve healing. This topic will review the proposed mechanisms, clinical use, and evidence for biologic therapies that have been the subject of peer-reviewed research and are used in the treatment of tendon and muscle injuries.</p><p class="headingAnchor" id="H770907909"><span class="h1">TERMINOLOGY AND BACKGROUND</span><span class="headingEndMark"> — </span>The United States Food and Drug Administration (FDA) states that biologic therapies are "sugars, proteins, or nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues." This review will not discuss sugars, proteins, or nucleic acids but will focus rather on cells and substances derived from tissues, as these are the biologic therapies used most often in the treatment of musculoskeletal injuries.</p><p>The biologic therapies used to treat muscle and tendon injuries can be divided broadly into two classes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood-derived therapies</strong>, which are reported to deliver cytokines and other substances locally at the site of injury and include injection of autologous whole blood (ABI), platelet-rich plasma (PRP), and extracted blood derivatives</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellular therapies</strong>, which involve introducing cells directly into local tissue (a process termed engrafting) and can include mesenchymal stem or stromal cells (MSCs), autologous tenocytes, and dermal fibroblasts</p><p></p><p>The number of clinics offering biologic therapies for muscle and tendon injuries has grown substantially. In Australia, in 2011, a single clinic offered "stem cell" therapy for musculoskeletal conditions but by 2014, over 40 clinics did so [<a href="#rid1">1</a>]. In the United States, the number of "stem cell" clinics has doubled annually over the same period, and it is estimated that 100 new clinics are opening each year [<a href="#rid2">2</a>].</p><p>A number of factors have contributed to the growing popularity of biologic therapies despite the dearth of high-quality clinical trials supporting their use. First, few (if any) established treatments improve the healing of musculoskeletal injuries. Biologic therapies are purported to meet this clinical need. Second, biologic therapies are easily administered via local injection by clinicians. In addition, the biotechnology companies that manufacture the equipment used to assist in the production of these therapies in clinics have marketed directly to clinicians and consumers.</p><p>Government regulation is another factor. In some countries, clinics have introduced these therapies prior to any regulation, and the resulting variation in geographic availability has led to "stem cell tourism." However, regulation is appearing, and clinicians considering referring patients for biologic therapies and administering such therapies themselves should be aware of national and international regulations regarding their use, including those put forward by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fvaccines-blood-biologics%2Fguidance-compliance-regulatory-information-biologics&amp;token=aZyuofSjX5GbTEX86A5h56ROUp6eFmy%2BbUDEaoSBprZAXb76%2F%2Fn04lSiwjzRrT%2BImaEpqw0KK2TsUmklkAeA8ULAoEKYWpIPrRbpDLINB3ZFMajBQpxxetFBkqB68KJ0&amp;TOPIC_ID=117566" target="_blank">FDA</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fhuman-regulatory%2Fresearch-development%2Fscientific-guidelines%2Fbiologicals%2Fbiologicals-finished-product&amp;token=lDR8vBOI9VB6cZl8V1MvGXpqfwPAYRJAT32JyBhMYkKfsrf97Zch%2FDZ0Ql0A9S%2B5n1jaYeP3D%2FIClCvIyBxHv2CKj9XA1Q5raHG5%2FOL2jlsMpOAXPVMaNOX7SM2UDlEcNmxY1%2BuJho1mmuAqV33FFg%3D%3D&amp;TOPIC_ID=117566" target="_blank">European Medicines Agency</a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tga.gov.au%2Fbiologicals-0&amp;token=9WvejqvB%2BuxLfR5G5o7V68gXRO0Hw9mTkGl2r6eMxVkO4SqEF6kyyNEnk7GCmm5K&amp;TOPIC_ID=117566" target="_blank">Australian Therapeutic Goods Administration</a>.</p><p class="headingAnchor" id="H3253537426"><span class="h1">PROPOSED MECHANISMS AND PRODUCTION OF BIOLOGIC THERAPIES</span></p><p class="headingAnchor" id="H2858691754"><span class="h2">Blood-derived therapies</span><span class="headingEndMark"> — </span>Blood-derived therapies involve the local administration of either blood or blood constituents treated to produce supraphysiologic concentrations of cytokines, which are purported to promote the growth and division of host repair cells or mediate the inflammatory process associated with injury.</p><p>The first blood-derived therapy used clinically was the local injection of autologous whole blood (ABI), but this has been superseded by platelet-rich plasma (PRP). Platelets are among the earliest cellular elements to be found at the site of tissue injury, where they are activated by exposure to such substances as thrombin and tissue collagen (the major protein in tendons). Once activated, platelets release their intracellular cytoplasmic granules. The platelet alpha-granules contain inflammatory and growth factors, including platelet-derived growth factor (PDGF), transforming growth factor (TGF)-beta, fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) [<a href="#rid3">3</a>].</p><p>PRP is defined as a platelet-rich concentrate with platelet levels greater than the baseline count in whole blood. It is manufactured using centrifugation of blood, which separates the denser red cells from the plasma. The plasma components are divided into a fine (white) buffy coat and an adjacent layer. The buffy coat contains leucocytes and most of the platelets. The adjacent layer of plasma is less rich in platelets and has few leucocytes.</p><p>There are a variety of techniques used to harvest the buffy coat, the adjacent plasma layer, or both. Some methods concentrate the buffy coat further using a "double spin." This process involves a second centrifugation of the supernatant obtained from the initial centrifugation and produces a more concentrated sample. Depending on the method, the number of platelets in PRP varies between one and nine times that of whole blood [<a href="#rid4">4</a>]. The techniques that produce lower concentrates of platelets typically produce lower concentrations of leucocytes as well. Conversely, techniques that produce higher platelet concentrations (eg, double spin) typically produce higher leucocyte concentrations. Hence, PRP is often referred to as "leucocyte rich" or "leucocyte poor."</p><p>The role of leucocytes (which contain enzymes such as collagenase) in tendon healing is controversial [<a href="#rid5">5</a>]. However, the results of a meta-analysis of randomized trials that differentiated between leukocyte-rich and leucocyte-poor PRP used to treat tendinopathy suggest that leukocyte-rich PRP may be more effective [<a href="#rid4">4</a>].</p><p>Biotechnology companies often provide centrifuges and disposable kits to clinicians; each technique has different preparation protocols (eg, volume of whole blood, plasma, or buffy coat; single or double spin; revolutions per minute; volume and concentration of PRP produced). Some practitioners add exogenous calcium salts to the PRP just prior to administration with the intention of ensuring platelet activation, while others assume that contact with tendon collagen will suffice. Administration protocols vary, but for tendon conditions, one to four intratendinous injections over two weeks is common [<a href="#rid6">6</a>]. There are no accepted exercise protocols or return-to-sport guidelines following PRP treatment.</p><p>As reflected in the discussion above, PRP is a general term describing a therapy with no gold standard of preparation or administration technique. This heterogeneity and the small number of controlled trials make it difficult to assess the efficacy of PRP for tendon and muscle injuries and disorders.</p><p class="headingAnchor" id="H3314437162"><span class="h2">Cell-based therapies</span><span class="headingEndMark"> — </span>Cell-based therapies for tendon and muscle conditions include the administration of undifferentiated stem cells, differentiated tenocytes, and nonhomologous dermal fibroblasts. Stem cell biology and the use of these products in other areas of medicine are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14598.html" rel="external">"Overview of stem cells"</a>.)</p><p>Unlike blood-derived therapies, cellular therapies are purported to produce a regenerative effect via their direct incorporation into injured tissue and adjacent tissue (ie, cellular engraftment). However, stem cells can remain unengrafted and produce cytokines that may contribute to tissue regeneration by promoting growth and differentiation of local cells.</p><p>There are several different types of stem cells, but they all possess the properties of proliferation and differentiation into adult cell lines. The mesenchymal stem or stromal cell (MSC) is a rare, undifferentiated multipotent stem cell considered to be the body's repair cell. It is relatively mature with less capacity for differentiation and proliferation compared with pluripotent stem cells. By definition, MSCs must demonstrate in vitro differentiation into fat, bone, and cartilage [<a href="#rid7">7</a>]; however, MSCs are also capable of differentiation into muscle, tendon, and ligament to varying degrees [<a href="#rid8">8</a>].</p><p>Importantly, undifferentiated MSCs receive local paracrine signals (cytokines), leading to proliferation and differentiation into the surrounding host tissue. Hence, if MSCs are placed within normal healthy bone, cartilage, or adipose tissue, they differentiate into that particular tissue. This property probably applies to all mesenchyme tissues, including muscle, tendon, and fibrous tissues. However, MSCs demonstrate little capacity for differentiation into nonmesenchymal tissue (eg, neural or hepatic cells).</p><p>MSCs are immunosuppressive and do not appear to initiate host rejection, so allogeneic cells may be used [<a href="#rid9">9</a>]. Even though allogeneic cells are highly cost effective, there are complex regulatory frameworks governing their use. MSCs appear to be a safe therapy, and published clinical trials involving local implantation to treat orthopedic conditions have not shown a significant risk of tumor formation, unintended differentiation, or other serious adverse events [<a href="#rid10">10,11</a>].</p><p>Bone marrow aspirate has been the traditional source for MSCs, although they comprise only 0.01 to 0.001 percent of nucleated marrow cells. Adipose tissue is a richer source of MSCs, and harvesting is less invasive [<a href="#rid12">12</a>]. However, in all tissue sources, the number of MSCs declines with age.</p><p>The manufacture of MSCs involves several distinct processes:</p><p class="bulletIndent1"><span class="glyph">●</span>Harvesting of cells by bone marrow- or lipoaspirate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolation of MSCs by plastic adherence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proliferation of MSCs in a culture medium (termed "expansion by passage"; up to five passages may be performed safely, and each requires up to a week)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Storage, usually by cryopreservation</p><p></p><p>(By definition, stem cells are harvested but not expanded, while stromal cells are expanded.)</p><p>These processes are costly, time consuming, and subject to considerable regulatory oversight.</p><p>Some clinicians, with assistance from biotechnology companies, are offering an alternative method of "stem cell manufacturing" that is less costly and less regulated but "nonquantitative." With this low-tech manufacturing procedure, there is no cellular isolation or proliferation, and the resulting number of MSCs is unknown. The final product is a solution of mononuclear cells, which contain relatively few MSCs (ie, less than 10 percent of the number found in adipose tissue or 3 percent in bone marrow) [<a href="#rid13">13,14</a>]. Technically, these aspirates should be termed "adipose stromal vascular fraction" or "bone marrow mononuclear cell concentrates," but they are often referred to as MSCs when described or marketed to patients and clinicians [<a href="#rid15">15</a>]. Clinicians should be aware of the difference between expanded MSCs (often used in research) and the nonexpanded heterogeneous stem cell therapies offered by most stem cell providers  (<a class="graphic graphic_table graphicRef121597" href="/z/d/graphic/121597.html" rel="external">table 1</a>).</p><p>In some countries, it is permitted to administer differentiated cells, which are not stem cells and therefore do not possess the potential to proliferate. These include autologous tenocytes (tendon cells), which have been expanded in vitro after harvesting a small piece of autologous tendon; and dermal fibroblasts, which form a scar tissue in tendons and are an example of a nonhomologous therapy. There is insufficient high-quality evidence of these cell-based therapies to justify further discussion. We believe they should be used only as part of well-designed research trials.</p><p class="headingAnchor" id="H1455374478"><span class="h1">INDICATIONS AND CONTRAINDICATIONS FOR BIOLOGIC THERAPIES</span></p><p class="headingAnchor" id="H1133988944"><span class="h2">Indications</span><span class="headingEndMark"> — </span>We believe that there is insufficient high-quality evidence to justify the use of biologic therapies for the treatment of tendon or muscle injuries outside of well-designed clinical trials. Despite the dearth of quality evidence, the manufacturers of biologic therapies claim that platelet-rich plasma (PRP), (nonexpanded) stem cell therapies, and combinations of these can be used for multiple clinical indications [<a href="#rid16">16</a>].</p><p>PRP is safe, relatively inexpensive, subject to minimal regulation, and easy to administer. Consequently, it is widely used to treat osteoarthritis and tendinopathy refractory to standard conservative therapy, rotator cuff tears, ligament injuries, and muscle tears [<a href="#rid16">16</a>].</p><p>Conversely, the manufacture of mesenchymal stem or stromal cells (MSCs) is costly, prolonged, and requires assistance from specialized biotechnology companies. Because MSCs are multipotent cells, they have been subjected to more rigorous government oversight than PRP and are considered investigational. A search of the National Institutes of Health <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=117566" target="_blank">clinical trial database</a> reveals that the majority of registered trials of MSC for the treatment of tendon injuries are either phase 1 or 2, and few have been completed or published. These trials include both expanded and nonexpanded MSCs for the treatment of a range of conditions, including isolated Achilles or lateral epicondyle tendinopathy and tissue scaffolding following surgical repair of rotator cuff injury.</p><p class="headingAnchor" id="H3986484971"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Biologics are not recommended for patients with an allergy to any manufacturing components (eg, <a class="drug drug_general" data-topicid="8898" href="/z/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a>), serious intercurrent illness (eg, acute infection causing fever), or local infection at or near the site of injection. PRP and MSCs are contraindicated in any patient with a malignancy or recent remission from a malignancy, with the exception of nonmetastasizing skin tumors such as squamous cell carcinoma or basal cell carcinoma. This is because of the risk of injecting malignant cells or growth factors that theoretically could accelerate a malignancy.</p><p>Local anesthetics may adversely affect platelet and stem cell function and should not be injected into the same location as the biologic therapy [<a href="#rid17">17,18</a>]. However, local anesthetics can be used in adjacent tissues and to block peripheral nerves, provided they do not mix with the biologic injection.</p><p>PRP therapy is not recommended in patients with thrombocytopenia or those who use nonsteroidal anti-inflammatories in the two weeks prior to bloodletting due to the effect on platelet numbers and function [<a href="#rid19">19</a>].</p><p>MSC therapies are not recommended in pregnant patients. While there is no research in this area, the proscription stems from theoretical risks to the fetus.</p><p>In theory, nonexpanded (same-day) MSC concentrates are relatively contraindicated for tendon disorders due to the low number of MSCs and the resulting larger volumes that must be injected intratendinously. This increases the risk of tendon damage and may lead to MSC extravasation, which could be harmful. Extravasated MSCs could potentially differentiate into undesired tissues, depending on signals from local adipose, osseous, or synovial tissues.</p><p class="headingAnchor" id="H632986380"><span class="h2">Biologic therapies and doping in sport</span><span class="headingEndMark"> — </span>Many elite athletes must abide by the World Anti-Doping Agency (WADA) regulations and are subject to drug testing requirements. According to the 2019 WADA Prohibited List, autologous PRP by local injection for the treatment of soft tissue injury is permitted. Systemic injection of blood products, including PRP, is not permitted. Local or systemic injection of individual purified growth factors derived from PRP is not permitted. Cellular products can be administered only if they are not used to enhance sports performance. Doping in sport and substances used for performance enhancement are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7475.html" rel="external">"Use of androgens and other hormones by athletes"</a> and  <a class="medical medical_review" href="/z/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport"</a> and  <a class="medical medical_review" href="/z/d/html/109127.html" rel="external">"Prescription and non-prescription medications permitted for performance enhancement"</a>.)</p><p>The use of both PRP and MSCs is addressed on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wada-ama.org%2Fen%2Fprohibited-list%23faq-anchor&amp;token=LyMsj877A%2Fv8KGeom5Z8pa8h4V2YuwJyT2l%2B3U%2FQDAhNIjZ2SbsxImDcLjF9EoG2HujKLPIk5xl8IqNy64aMpA%3D%3D&amp;TOPIC_ID=117566" target="_blank">WADA "Q&amp;A" website</a> [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1819145863"><span class="h1">BIOLOGIC THERAPIES FOR TENDON INJURIES</span></p><p class="headingAnchor" id="H917524566"><span class="h2">Types of tendon injuries treated</span></p><p class="headingAnchor" id="H353690545"><span class="h3">Degenerative overuse tendon injury</span><span class="headingEndMark"> — </span>Tendon injuries commonly occur from overuse, particularly overuse involving energy-storage-and-release (spring) loads (eg, jumping) and compressive loads (eg, squatting with weight) [<a href="#rid21">21</a>]. The cumulative effects of overuse can produce tendon pathology, usually degeneration, that may become symptomatic and possibly progress to rupture. Sometimes, intrasubstance tendon tears develop, although the clinical diagnosis of these is problematic and they may not be clinically meaningful [<a href="#rid22">22</a>].</p><p>Degenerative tendon is characterized by a progressive loss of matrix integrity (eg, collagen disorganization, increase in proteoglycans) [<a href="#rid23">23,24</a>] and leads to a thickened tendon with a matrix that cannot transmit load, an important stimulus for tissue repair. As no acute injury is involved, and there is no inflammation, important stimuli for tendon repair are missing. The result is that overuse tendon pathology does not heal.</p><p class="headingAnchor" id="H2073609121"><span class="h3">Tendon rupture</span><span class="headingEndMark"> — </span>Tendons that rupture have degenerative pathology that is often asymptomatic [<a href="#rid25">25</a>]. Tendons rupture when the load placed on the tendon exceeds the capacity of the remaining normal part of the tendon. Hence, a profoundly degenerative tendon can rupture with little load (stepping off a curb); conversely, a gymnast can rupture a minimally degenerative tendon due to the high landing loads (up to 17 times body weight) that their sport entails. The injury results in bleeding, which causes an inflammatory, proliferative, and maturative response that in turn produces extensive change to the cells and matrix. This response results in a tendon that is two to three times thicker than the original and is completely different from that seen with an overuse tendon injury.</p><p class="headingAnchor" id="H1607082763"><span class="h2">Studies of PRP and ABI for tendon injury</span></p><p class="headingAnchor" id="H3333244888"><span class="h3">Medical therapy</span><span class="headingEndMark"> — </span>The results of studies of autologous whole blood injection (ABI) and platelet-rich plasma (PRP) for the treatment of tendon injuries are contradictory, but most show no clear benefit. A 2014 systematic review of 19 randomized and quasi-randomized trials of PRP for musculoskeletal soft tissue injuries, involving 1088 participants, noted the following [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>"The evidence for all primary outcomes was judged as being of very low quality."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Methods for preparing and quantifying PRP therapies lack standardization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence to support the use of PRP therapies for treating muscle and tendon injuries is lacking, both overall and for specific conditions.</p><p></p><p>The authors' review of 16 randomized trials (four published after the 2014 systematic review) assessing the effectiveness of ABI or PRP for overuse tendinopathy found that 11 reported no difference in clinically important outcomes [<a href="#rid27">27-42</a>]. Subsequent studies have reported similar findings [<a href="#rid43">43,44</a>]. A small, well-performed trial comparing leukocyte-rich PRP with leukocyte-poor PRP and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> for the treatment of patellar tendinopathy (in addition, all participants completed the same rehabilitation program) found no difference in outcome at 12 weeks and 12 months [<a href="#rid45">45</a>].</p><p>As reported in the systematic review, the quality of many of the clinical studies of PRP is limited, and many are at high risk of bias. The following are among the common methodologic problems noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Small number of participants </p><p class="bulletIndent1"><span class="glyph">●</span>Blinding of participants and/or outcome assessors not performed or not described</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment preparation not standardized among trials</p><p class="bulletIndent1"><span class="glyph">●</span>Outcome measures often focused on pain; healing of tendon tissue not considered</p><p></p><p>Tendon injuries are not monolithic but involve a number of considerations not accounted for in many trials that may be a source of some of the contradictory outcomes reported. Such considerations include whether the injury involves an upper or lower extremity, a mid-tendon or entheseal tendon, an intact collagen scaffold or tendon tear, and bursal involvement or not. Additional problems may be related to specific treatments. For therapies that are "innovative," expensive, and ritualistic, the placebo effect must be considered carefully [<a href="#rid46">46,47</a>].</p><p class="headingAnchor" id="H3153314086"><span class="h3">Adjunct to surgical repair</span><span class="headingEndMark"> — </span>The great majority of randomized trials have reported no clinically significant benefit at long-term follow-up from the addition of PRP therapy to surgical repair of injured rotator cuff or Achilles tendons [<a href="#rid48">48,49</a>]. Heterogeneity among studies and poor methodologic quality limit much of the available evidence [<a href="#rid50">50</a>]. Therefore, we do not recommend that PRP be used as adjunctive therapy for tendon surgery outside of well-designed clinical trials.</p><p>In addition to published systematic reviews, the authors assessed 13 randomized trials comparing rotator cuff or Achilles tendon repair with or without adjunctive treatment using PRP [<a href="#rid51">51-63</a>]. Only one of the trials reported a clinically important improvement in tendon healing and functional outcome at long-term follow-up in patients given PRP [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H904422949"><span class="h2">Studies of stem cell therapy for tendon injury</span><span class="headingEndMark"> — </span>Additional research is needed to determine whether mesenchymal stem or stromal cells (MSCs) are an effective treatment for tendinopathy in humans and, if found to be effective, to establish the best MSC-harvesting source and the number of MSCs to inject.</p><p>The potential benefits of MSC therapy in tendon disorders was first described in the equine thoroughbred industry. Racehorses are prone to developing superficial digital flexor tendinopathy, and the intratendinous implantation of 10 to 20 x 10<sup>6</sup> expanded autologous bone marrow MSCs suspended in 2 mL of solution has been reported to be beneficial. The equine reinjury rate after MSC therapy was 27.4 percent, which is nearly one-half the rate of alternative nonsurgical treatments [<a href="#rid64">64</a>]. Subsequent postmortem studies have shown minimal evidence of tendinopathy after MSC implantation.</p><p>Clinical evidence supporting the use of MSCs in humans is limited and unconvincing. A systematic review identified four published clinical trials with a total of 79 patients [<a href="#rid65">65</a>]. All four trials describe positive results without serious adverse outcomes, but only one trial used expanded (allogeneic) MSCs, and none of the trials involved contemporaneous controls. The authors found that all trials were at high risk of bias, and evidence did not support the use of stem cells to treat tendon disorders.</p><p class="headingAnchor" id="H3910940582"><span class="h1">BIOLOGIC THERAPIES FOR MUSCLE INJURIES</span></p><p class="headingAnchor" id="H835663273"><span class="h2">Types of muscle injuries treated</span><span class="headingEndMark"> — </span>Skeletal muscle is frequently injured due to load-related strains during activity. Proponents of biologic therapies claim they are effective treatments for such injuries. Skeletal muscle is also susceptible to tears, contusions, lacerations, crush injury, and age-related atrophy (sarcopenia).</p><p>Muscle strains (commonly referred to as "pulls" or "tears") occur when the load placed on the muscle exceeds the muscle's capacity to resist the load. This causes acute injury of the muscle fibers at the muscle-tendon junction (MTJ). Strains occur at the MTJ within the muscle belly or involve the intramuscular connective tissue. Muscle strain results in bleeding from the injured tissue that initiates an inflammatory, proliferative, and maturative (regenerative) response. Many cytokine growth factors are released, and cellular responses occur during a complex healing process.</p><p>The established treatment of muscle-strain injuries emphasizes active recovery, including exercise-based interventions [<a href="#rid66">66</a>]. An important consideration with muscle-strain injuries is recurrence or reinjury.</p><p class="headingAnchor" id="H568698451"><span class="h2">Studies of PRP use for muscle injury</span><span class="headingEndMark"> — </span>Muscle injuries are heterogeneous, varying in the mechanism, site of injury, extent of injury, and the presence or absence of connective tissue involvement. Depending on the nature of the injury, a range of therapies may be of potential use. Nevertheless, few randomized trials of platelet-rich plasma (PRP) for the treatment of muscle injuries have been performed, and results have been mixed. Thus, no conclusions can be drawn about the effectiveness of PRP therapy for acute muscle injury.</p><p>The limited evidence available includes the following [<a href="#rid67">67-69</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five randomized trials of moderate overall quality involving 268 patients with grade I or II acute muscle injury reported that treatment with PRP led to earlier return to sport (mean difference -5.57 days; 95% CI -9.57 to -1.58) but no statistically significant difference in reinjury rates [<a href="#rid67">67</a>]. The large majority of patients were men, and hamstring strains were the most common injury treated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perhaps the best trial included in the meta-analysis described above was a multicenter randomized trial of 80 competitive and recreational athletes with acute hamstring strains. In this trial, patients treated with PRP injection did not return to play more quickly and did not experience lower rates of reinjury at either two months or one year (hazard ratio [HR] 0.89; 95% CI 0.38-2.13) compared with those treated with placebo [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of 75 athletes with acute grade II muscle strains, patients treated with physical therapy plus PRP injection returned to play sooner than those treated with physical therapy alone (21 versus 25 days) and experienced less pain throughout the study, but the rate of reinjury at two years was not statistically different [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H619191891"><span class="h2">Studies of MSC use for muscle injury</span><span class="headingEndMark"> — </span>Stem cell therapies for skeletal muscle injuries and disorders remain investigational and have yet to be studied sufficiently in clinical trials. These therapies are the subject of research for a range of uses.</p><p>Skeletal muscle has the capacity to repair and regenerate due to the presence of muscle satellite cells, which are unipotent differentiated cells capable of proliferation and engraftment. Skeletal muscle is also a source of multipotent mesenchymal stem cells and has been used as a harvesting source to treat other pathologies.</p><p>Most muscle-strain injuries heal well, but an exception is injury complicated by muscle fibrosis. In this condition, local mesenchymal stem or stromal cells (MSCs) differentiate into myofibroblasts rather than myoblasts/satellite cells, and this is thought to be due to the production of local cytokines [<a href="#rid70">70,71</a>]. Therefore, in theory, stem cells injected into such tissue could differentiate into additional scar rather than muscle.</p><p>Ongoing research is investigating the use of MSCs combined with tissue-engineering scaffolds to treat massive posttraumatic muscle loss and postdenervation muscle injury. In some of these trials, MSCs are predifferentiated into myoblasts/satellite cells so that inappropriate differentiation does not occur.</p><p>Research is ongoing into the use of MSCs in reversing nonskeletal muscle pathology, including fibrosis following myocardial infarction and urinary incontinence due to detrusor instability. There are a number of medical conditions associated with systemic skeletal muscle wasting, including disuse atrophy, cancer cachexia, muscular dystrophy, and sarcopenia [<a href="#rid72">72</a>]. Theoretically, systemic MSCs could be useful for these conditions, but methods of stem cell delivery to peripheral muscle have not yet been established. If this problem is overcome, any such therapy would have a significant potential for sport doping.</p><p class="headingAnchor" id="H1811907019"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117959.html" rel="external">"Society guideline links: General issues in muscle and tendon injury diagnosis and management"</a>.)</p><p class="headingAnchor" id="H2827233597"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Basic types of biologic therapies</strong> – The biologic therapies used to treat muscle and tendon injuries are described in greater detail in the text but can be divided broadly into two classes (see <a class="local">'Terminology and background'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood-derived therapies</strong> include injection of autologous whole blood (ABI), platelet-rich plasma (PRP), and extracted blood derivatives. They are injected at the site of injury and are purported to deliver supraphysiologic concentrations of cytokines and other substances that promote growth and repair and mediate the inflammatory process. (See <a class="local">'Blood-derived therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cellular therapies</strong> include mesenchymal stem or stromal cells (MSCs), autologous tenocytes, and dermal fibroblasts; and involve introducing cells directly into local tissue (a process termed "engrafting"), where they purportedly have regenerative effects. (See <a class="local">'Cell-based therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Biologic treatments are generally regarded as low risk, but they are not recommended for patients with an allergy to any manufacturing components (eg, <a class="drug drug_general" data-topicid="8898" href="/z/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a>), serious intercurrent illness (eg, acute infection causing fever), or local infection at or near the site of injection. PRP and MSCs are contraindicated in any patient with a malignancy or recent remission from a malignancy, with the exception of nonmetastasizing skin tumors such as squamous cell carcinoma or basal cell carcinoma. (See <a class="local">'Indications and contraindications for biologic therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet-rich plasma (PRP) treatments</strong> – PRP therapy describes a treatment without standardization of manufacturing methodology, administration schedules, or return-to-exercise guidelines, meaning efficacy is hard to assess. The preponderance of the evidence does not support the efficacy of PRP for treating tendon disorders. There is virtually no high-quality evidence to support the use of PRP in association with surgical treatments, and there have been insufficient clinical trials to determine if PRP has any role in muscle healing. (See <a class="local">'Biologic therapies for tendon injuries'</a> above and <a class="local">'Biologic therapies for muscle injuries'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mesenchymal cell treatments</strong> – MSCs remain an investigational therapy for tendon and muscle injuries that has yet to be studied in well-performed randomized trials. (See <a class="local">'Studies of stem cell therapy for tendon injury'</a> above and <a class="local">'Studies of MSC use for muscle injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety and lack of proven effectiveness</strong> – Evidence from clinical trials suggests that biologic therapies, including PRP and MSCs, are safe and do not cause significant adverse effects in tendon or muscle tissue. However, evidence for their efficacy is sparse and limited in quality, and we do not recommend their use outside of well-designed clinical trials.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Munsie M, Pera M. Regulatory loophole enables unproven autologous cell therapies to thrive in Australia. Stem Cells Dev 2014; 23 Suppl 1:34.</a></li><li><a class="nounderline abstract_t">Rubin R. Unproven but Profitable: The Boom in US Stem Cell Clinics. JAMA 2018; 320:1421.</a></li><li><a class="nounderline abstract_t">Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114:1502.</a></li><li><a class="nounderline abstract_t">Fitzpatrick J, Bulsara M, Zheng MH. The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy. Am J Sports Med 2017; 45:226.</a></li><li><a class="nounderline abstract_t">Yerlikaya M, Talay Çaliş H, Tomruk Sütbeyaz S, et al. Comparison of Effects of Leukocyte-Rich and Leukocyte-Poor Platelet-Rich Plasma on Pain and Functionality in Patients With Lateral Epicondylitis. Arch Rheumatol 2018; 33:73.</a></li><li><a class="nounderline abstract_t">Robins RJ. Platelet Rich Plasma: Current Indications and Use In Orthopaedic Care. Medical Research Archives 2017; 5.</a></li><li><a class="nounderline abstract_t">Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315.</a></li><li><a class="nounderline abstract_t">Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther 2007; 9:204.</a></li><li><a class="nounderline abstract_t">Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2:8.</a></li><li><a class="nounderline abstract_t">Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012; 7:e47559.</a></li><li><a class="nounderline abstract_t">Peeters CM, Leijs MJ, Reijman M, et al. Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review. Osteoarthritis Cartilage 2013; 21:1465.</a></li><li><a class="nounderline abstract_t">Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9:12.</a></li><li><a class="nounderline abstract_t">Jurgens WJ, Oedayrajsingh-Varma MJ, Helder MN, et al. Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies. Cell Tissue Res 2008; 332:415.</a></li><li><a class="nounderline abstract_t">Imam MA, Holton J, Horriat S, et al. A systematic review of the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology. SICOT J 2017; 3:58.</a></li><li><a class="nounderline abstract_t">Lee JI, Lee S, Han Y, Balolong E Jr. Labeling Cells Correctly as Stromal Vascular Fraction Matters. Arthroscopy 2017; 33:1438.</a></li><li><a class="nounderline abstract_t">Hsu WK, Mishra A, Rodeo SR, et al. Platelet-rich plasma in orthopaedic applications: evidence-based recommendations for treatment. J Am Acad Orthop Surg 2013; 21:739.</a></li><li><a class="nounderline abstract_t">Bausset O, Magalon J, Giraudo L, et al. Impact of local anaesthetics and needle calibres used for painless PRP injections on platelet functionality. Muscles Ligaments Tendons J 2014; 4:18.</a></li><li><a class="nounderline abstract_t">Lucchinetti E, Awad AE, Rahman M, et al. Antiproliferative effects of local anesthetics on mesenchymal stem cells: potential implications for tumor spreading and wound healing. Anesthesiology 2012; 116:841.</a></li><li><a class="nounderline abstract_t">Schippinger G, Prüller F, Divjak M, et al. Autologous Platelet-Rich Plasma Preparations: Influence of Nonsteroidal Anti-inflammatory Drugs on Platelet Function. Orthop J Sports Med 2015; 3:2325967115588896.</a></li><li class="breakAll">The Prohibited List. World Anti-Doping Agency. Available at: https://www.wada-ama.org/en/prohibited-list (Accessed on November 01, 2022).</li><li><a class="nounderline abstract_t">Cook JL, Purdam C. Is compressive load a factor in the development of tendinopathy? Br J Sports Med 2012; 46:163.</a></li><li><a class="nounderline abstract_t">Docking SI, Cook J, Chen S, et al. Identification and differentiation of gluteus medius tendon pathology using ultrasound and magnetic resonance imaging. Musculoskelet Sci Pract 2019; 41:1.</a></li><li><a class="nounderline abstract_t">Cook JL, Purdam CR. Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 2009; 43:409.</a></li><li><a class="nounderline abstract_t">Cook JL, Rio E, Purdam CR, Docking SI. Revisiting the continuum model of tendon pathology: what is its merit in clinical practice and research? Br J Sports Med 2016; 50:1187.</a></li><li><a class="nounderline abstract_t">Kannus P, Józsa L. Histopathological changes preceding spontaneous rupture of a tendon. A controlled study of 891 patients. J Bone Joint Surg Am 1991; 73:1507.</a></li><li><a class="nounderline abstract_t">Moraes VY, Lenza M, Tamaoki MJ, et al. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev 2013; :CD010071.</a></li><li><a class="nounderline abstract_t">Krogh TP, Ellingsen T, Christensen R, et al. Ultrasound-Guided Injection Therapy of Achilles Tendinopathy With Platelet-Rich Plasma or Saline: A Randomized, Blinded, Placebo-Controlled Trial. Am J Sports Med 2016; 44:1990.</a></li><li><a class="nounderline abstract_t">Davenport KL, Campos JS, Nguyen J, et al. Ultrasound-Guided Intratendinous Injections With Platelet-Rich Plasma or Autologous Whole Blood for Treatment of Proximal Hamstring Tendinopathy: A Double-Blind Randomized Controlled Trial. J Ultrasound Med 2015; 34:1455.</a></li><li><a class="nounderline abstract_t">Pearson J, Rowlands D, Highet R. Autologous blood injection to treat achilles tendinopathy? A randomized controlled trial. J Sport Rehabil 2012; 21:218.</a></li><li><a class="nounderline abstract_t">Wolf JM, Ozer K, Scott F, et al. Comparison of autologous blood, corticosteroid, and saline injection in the treatment of lateral epicondylitis: a prospective, randomized, controlled multicenter study. J Hand Surg Am 2011; 36:1269.</a></li><li><a class="nounderline abstract_t">Kazemi M, Azma K, Tavana B, et al. Autologous blood versus corticosteroid local injection in the short-term treatment of lateral elbow tendinopathy: a randomized clinical trial of efficacy. Am J Phys Med Rehabil 2010; 89:660.</a></li><li><a class="nounderline abstract_t">Arik HO, Kose O, Guler F, et al. Injection of autologous blood versus corticosteroid for lateral epicondylitis: a randomised controlled study. J Orthop Surg (Hong Kong) 2014; 22:333.</a></li><li><a class="nounderline abstract_t">Boesen AP, Hansen R, Boesen MI, et al. Effect of High-Volume Injection, Platelet-Rich Plasma, and Sham Treatment in Chronic Midportion Achilles Tendinopathy: A Randomized Double-Blinded Prospective Study. Am J Sports Med 2017; 45:2034.</a></li><li><a class="nounderline abstract_t">Creaney L, Wallace A, Curtis M, Connell D. Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections. Br J Sports Med 2011; 45:966.</a></li><li><a class="nounderline abstract_t">de Jonge S, de Vos RJ, Weir A, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med 2011; 39:1623.</a></li><li><a class="nounderline abstract_t">Thanasas C, Papadimitriou G, Charalambidis C, et al. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. Am J Sports Med 2011; 39:2130.</a></li><li><a class="nounderline abstract_t">Ozturan KE, Yucel I, Cakici H, et al. Autologous blood and corticosteroid injection and extracoporeal shock wave therapy in the treatment of lateral epicondylitis. Orthopedics 2010; 33:84.</a></li><li><a class="nounderline abstract_t">Dragoo JL, Wasterlain AS, Braun HJ, Nead KT. Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial. Am J Sports Med 2014; 42:610.</a></li><li><a class="nounderline abstract_t">Kesikburun S, Tan AK, Yilmaz B, et al. Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up. Am J Sports Med 2013; 41:2609.</a></li><li><a class="nounderline abstract_t">Mishra AK, Skrepnik NV, Edwards SG, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med 2014; 42:463.</a></li><li><a class="nounderline abstract_t">Gautam VK, Verma S, Batra S, et al. Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: clinical and ultrasonographic evaluation. J Orthop Surg (Hong Kong) 2015; 23:1.</a></li><li><a class="nounderline abstract_t">Krogh TP, Fredberg U, Stengaard-Pedersen K, et al. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med 2013; 41:625.</a></li><li><a class="nounderline abstract_t">Keene DJ, Alsousou J, Harrison P, et al. Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial. BMJ 2019; 367:l6132.</a></li><li><a class="nounderline abstract_t">Boesen AP, Boesen MI, Hansen R, et al. Effect of Platelet-Rich Plasma on Nonsurgically Treated Acute Achilles Tendon Ruptures: A Randomized, Double-Blinded Prospective Study. Am J Sports Med 2020; 48:2268.</a></li><li><a class="nounderline abstract_t">Scott A, LaPrade RF, Harmon KG, et al. Platelet-Rich Plasma for Patellar Tendinopathy: A Randomized Controlled Trial of Leukocyte-Rich PRP or Leukocyte-Poor PRP Versus Saline. Am J Sports Med 2019; 47:1654.</a></li><li><a class="nounderline abstract_t">Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA 2008; 299:1016.</a></li><li><a class="nounderline abstract_t">Howick J, Friedemann C, Tsakok M, et al. Are treatments more effective than placebos? A systematic review and meta-analysis. PLoS One 2013; 8:e62599.</a></li><li><a class="nounderline abstract_t">Warth RJ, Dornan GJ, James EW, et al. Clinical and structural outcomes after arthroscopic repair of full-thickness rotator cuff tears with and without platelet-rich product supplementation: a meta-analysis and meta-regression. Arthroscopy 2015; 31:306.</a></li><li><a class="nounderline abstract_t">Saltzman BM, Jain A, Campbell KA, et al. Does the Use of Platelet-Rich Plasma at the Time of Surgery Improve Clinical Outcomes in Arthroscopic Rotator Cuff Repair When Compared With Control Cohorts? A Systematic Review of Meta-analyses. Arthroscopy 2016; 32:906.</a></li><li><a class="nounderline abstract_t">Chen X, Jones IA, Togashi R, et al. Use of Platelet-Rich Plasma for the Improvement of Pain and Function in Rotator Cuff Tears: A Systematic Review and Meta-analysis With Bias Assessment. Am J Sports Med 2020; 48:2028.</a></li><li><a class="nounderline abstract_t">Rodeo SA, Delos D, Williams RJ, et al. The effect of platelet-rich fibrin matrix on rotator cuff tendon healing: a prospective, randomized clinical study. Am J Sports Med 2012; 40:1234.</a></li><li><a class="nounderline abstract_t">Zumstein MA, Rumian A, Thélu CÉ, et al. SECEC Research Grant 2008 II: Use of platelet- and leucocyte-rich fibrin (L-PRF) does not affect late rotator cuff tendon healing: a prospective randomized controlled study. J Shoulder Elbow Surg 2016; 25:2.</a></li><li><a class="nounderline abstract_t">Wang A, McCann P, Colliver J, et al. Do postoperative platelet-rich plasma injections accelerate early tendon healing and functional recovery after arthroscopic supraspinatus repair? A randomized controlled trial. Am J Sports Med 2015; 43:1430.</a></li><li><a class="nounderline abstract_t">Flury M, Rickenbacher D, Schwyzer HK, et al. Does Pure Platelet-Rich Plasma Affect Postoperative Clinical Outcomes After Arthroscopic Rotator Cuff Repair? A Randomized Controlled Trial. Am J Sports Med 2016; 44:2136.</a></li><li><a class="nounderline abstract_t">Pandey V, Bandi A, Madi S, et al. Does application of moderately concentrated platelet-rich plasma improve clinical and structural outcome after arthroscopic repair of medium-sized to large rotator cuff tear? A randomized controlled trial. J Shoulder Elbow Surg 2016; 25:1312.</a></li><li><a class="nounderline abstract_t">Zou J, Mo X, Shi Z, et al. A Prospective Study of Platelet-Rich Plasma as Biological Augmentation for Acute Achilles Tendon Rupture Repair. Biomed Res Int 2016; 2016:9364170.</a></li><li><a class="nounderline abstract_t">Jo CH, Shin JS, Shin WH, et al. Platelet-rich plasma for arthroscopic repair of medium to large rotator cuff tears: a randomized controlled trial. Am J Sports Med 2015; 43:2102.</a></li><li><a class="nounderline abstract_t">Ebert JR, Wang A, Smith A, et al. A Midterm Evaluation of Postoperative Platelet-Rich Plasma Injections on Arthroscopic Supraspinatus Repair: A Randomized Controlled Trial. Am J Sports Med 2017; 45:2965.</a></li><li><a class="nounderline abstract_t">Malavolta EA, Gracitelli ME, Ferreira Neto AA, et al. Platelet-rich plasma in rotator cuff repair: a prospective randomized study. Am J Sports Med 2014; 42:2446.</a></li><li><a class="nounderline abstract_t">Castricini R, Longo UG, De Benedetto M, et al. Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial. Am J Sports Med 2011; 39:258.</a></li><li><a class="nounderline abstract_t">De Carli A, Lanzetti RM, Ciompi A, et al. Can platelet-rich plasma have a role in Achilles tendon surgical repair? Knee Surg Sports Traumatol Arthrosc 2016; 24:2231.</a></li><li><a class="nounderline abstract_t">Schepull T, Kvist J, Norrman H, et al. Autologous platelets have no effect on the healing of human achilles tendon ruptures: a randomized single-blind study. Am J Sports Med 2011; 39:38.</a></li><li><a class="nounderline abstract_t">Randelli P, Arrigoni P, Ragone V, et al. Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up. J Shoulder Elbow Surg 2011; 20:518.</a></li><li><a class="nounderline abstract_t">Godwin EE, Young NJ, Dudhia J, et al. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon. Equine Vet J 2012; 44:25.</a></li><li><a class="nounderline abstract_t">Pas HIMFL, Moen MH, Haisma HJ, Winters M. No evidence for the use of stem cell therapy for tendon disorders: a systematic review. Br J Sports Med 2017; 51:996.</a></li><li><a class="nounderline abstract_t">Hölmich P, Uhrskou P, Ulnits L, et al. Effectiveness of active physical training as treatment for long-standing adductor-related groin pain in athletes: randomised trial. Lancet 1999; 353:439.</a></li><li><a class="nounderline abstract_t">Sheth U, Dwyer T, Smith I, et al. Does Platelet-Rich Plasma Lead to Earlier Return to Sport When Compared With Conservative Treatment in Acute Muscle Injuries? A Systematic Review and Meta-analysis. Arthroscopy 2018; 34:281.</a></li><li><a class="nounderline abstract_t">Rossi LA, Molina Rómoli AR, Bertona Altieri BA, et al. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc 2017; 25:3319.</a></li><li><a class="nounderline abstract_t">Reurink G, Goudswaard GJ, Moen MH, et al. Rationale, secondary outcome scores and 1-year follow-up of a randomised trial of platelet-rich plasma injections in acute hamstring muscle injury: the Dutch Hamstring Injection Therapy study. Br J Sports Med 2015; 49:1206.</a></li><li><a class="nounderline abstract_t">Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol 2002; 161:895.</a></li><li><a class="nounderline abstract_t">Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 2002; 227:301.</a></li><li><a class="nounderline abstract_t">Maclean S, Khan WS, Malik AA, et al. The potential of stem cells in the treatment of skeletal muscle injury and disease. Stem Cells Int 2012; 2012:282348.</a></li></ol></div><div id="topicVersionRevision">Topic 117566 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25457959" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Regulatory loophole enables unproven autologous cell therapies to thrive in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326510" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Unproven but Profitable: The Boom in US Stem Cell Clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509939" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27268111" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29900994" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of Effects of Leukocyte-Rich and Leukocyte-Poor Platelet-Rich Plasma on Pain and Functionality in Patients With Lateral Epicondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Platelet Rich Plasma: Current Indications and Use In Orthopaedic Care</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923606" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17316462" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16045800" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mesenchymal stem cells avoid allogeneic rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23133515" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23831631" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21569606" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18379826" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28990575" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A systematic review of the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28779793" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Labeling Cells Correctly as Stromal Vascular Fraction Matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24292930" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Platelet-rich plasma in orthopaedic applications: evidence-based recommendations for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24932442" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of local anaesthetics and needle calibres used for painless PRP injections on platelet functionality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343474" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antiproliferative effects of local anesthetics on mesenchymal stem cells: potential implications for tumor spreading and wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26665098" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Autologous Platelet-Rich Plasma Preparations: Influence of Nonsteroidal Anti-inflammatory Drugs on Platelet Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26665098" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Autologous Platelet-Rich Plasma Preparations: Influence of Nonsteroidal Anti-inflammatory Drugs on Platelet Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22113234" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Is compressive load a factor in the development of tendinopathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763889" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Identification and differentiation of gluteus medius tendon pathology using ultrasound and magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812414" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27127294" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Revisiting the continuum model of tendon pathology: what is its merit in clinical practice and research?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1748700" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Histopathological changes preceding spontaneous rupture of a tendon. A controlled study of 891 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24363098" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Platelet-rich therapies for musculoskeletal soft tissue injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27257167" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ultrasound-Guided Injection Therapy of Achilles Tendinopathy With Platelet-Rich Plasma or Saline: A Randomized, Blinded, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26206832" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ultrasound-Guided Intratendinous Injections With Platelet-Rich Plasma or Autologous Whole Blood for Treatment of Proximal Hamstring Tendinopathy: A Double-Blind Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22104390" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Autologous blood injection to treat achilles tendinopathy? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21705157" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of autologous blood, corticosteroid, and saline injection in the treatment of lateral epicondylitis: a prospective, randomized, controlled multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463564" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Autologous blood versus corticosteroid local injection in the short-term treatment of lateral elbow tendinopathy: a randomized clinical trial of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25550013" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Injection of autologous blood versus corticosteroid for lateral epicondylitis: a randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28530451" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of High-Volume Injection, Platelet-Rich Plasma, and Sham Treatment in Chronic Midportion Achilles Tendinopathy: A Randomized Double-Blinded Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406450" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21602565" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813443" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20192142" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Autologous blood and corticosteroid injection and extracoporeal shock wave therapy in the treatment of lateral epicondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24481828" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23893418" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23825183" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25920633" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: clinical and ultrasonographic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23328738" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31748208" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32485112" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of Platelet-Rich Plasma on Nonsurgically Treated Acute Achilles Tendon Ruptures: A Randomized, Double-Blinded Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31038979" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Platelet-Rich Plasma for Patellar Tendinopathy: A Randomized Controlled Trial of Leukocyte-Rich PRP or Leukocyte-Poor PRP Versus Saline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319411" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Commercial features of placebo and therapeutic efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690944" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Are treatments more effective than placebos? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25450417" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical and structural outcomes after arthroscopic repair of full-thickness rotator cuff tears with and without platelet-rich product supplementation: a meta-analysis and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26725454" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Does the Use of Platelet-Rich Plasma at the Time of Surgery Improve Clinical Outcomes in Arthroscopic Rotator Cuff Repair When Compared With Control Cohorts? A Systematic Review of Meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31743037" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of Platelet-Rich Plasma for the Improvement of Pain and Function in Rotator Cuff Tears: A Systematic Review and Meta-analysis With Bias Assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495146" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The effect of platelet-rich fibrin matrix on rotator cuff tendon healing: a prospective, randomized clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687471" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : SECEC Research Grant 2008 II: Use of platelet- and leucocyte-rich fibrin (L-PRF) does not affect late rotator cuff tendon healing: a prospective randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25790835" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Do postoperative platelet-rich plasma injections accelerate early tendon healing and functional recovery after arthroscopic supraspinatus repair? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27184542" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Does Pure Platelet-Rich Plasma Affect Postoperative Clinical Outcomes After Arthroscopic Rotator Cuff Repair? A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27262412" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Does application of moderately concentrated platelet-rich plasma improve clinical and structural outcome after arthroscopic repair of medium-sized to large rotator cuff tear? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28116306" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A Prospective Study of Platelet-Rich Plasma as Biological Augmentation for Acute Achilles Tendon Rupture Repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26015443" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Platelet-rich plasma for arthroscopic repair of medium to large rotator cuff tears: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28806095" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Midterm Evaluation of Postoperative Platelet-Rich Plasma Injections on Arthroscopic Supraspinatus Repair: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25086065" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Platelet-rich plasma in rotator cuff repair: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21160018" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25796585" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Can platelet-rich plasma have a role in Achilles tendon surgical repair?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051425" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Autologous platelets have no effect on the healing of human achilles tendon ruptures: a randomized single-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21570659" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21615465" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28077355" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : No evidence for the use of stem cell therapy for tendon disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989713" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effectiveness of active physical training as treatment for long-standing adductor-related groin pain in athletes: randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28800920" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Does Platelet-Rich Plasma Lead to Earlier Return to Sport When Compared With Conservative Treatment in Acute Muscle Injuries? A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085364" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940636" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Rationale, secondary outcome scores and 1-year follow-up of a randomised trial of platelet-rich plasma injections in acute hamstring muscle injury: the Dutch Hamstring Injection Therapy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12213718" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11976400" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Factors involved in the regulation of type I collagen gene expression: implication in fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22220178" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The potential of stem cells in the treatment of skeletal muscle injury and disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
